Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Lenvima/Keytruda Combo Shows around 30% ORR in Triple Negative Breast Cancer, Ovarian Cancer: PII
September 24, 2020
- Keytruda’s 1st Line Gastric Cancer Submission Pulled in Japan
September 23, 2020
- 42 Nippon Chemiphar Reps to Hit Exit under Voluntary Redundancy
September 23, 2020
- Sanofi’s Dupixent Adds Pen Formulation in Japan
September 23, 2020
- Lucentis Biosimilar Filed in Japan; Senju/Gene Techno Eye 2021 Approval
September 23, 2020
- Kyowa Kirin Sees Steady Switch to Nesp Biosame, but Biosimilars Closing in at Full Steam
September 18, 2020
- Santen Gobbles Up US Ophthalmic Player for US$225 Million
September 18, 2020
- Towa, Nichi-Iko Recalling Some Metformin Products over Carcinogen Risks, Follow 2 Makers
September 17, 2020
- Nichi-Iko to Resume Normal Shipments of Cefazolin Starting October 1
September 17, 2020
- Takeda Opens New Manufacturing Site for Cell Therapy Products in Boston
September 17, 2020
- Takeda to Offload TachoSil to Corza Health
September 17, 2020
- Amgen Files Erenumab for Migraine Prevention in Japan
September 17, 2020
- SanBio to Start Talks with PMDA over Late-Stage Study of SB623 in Ischemic, Hemorrhagic Strokes: COO
September 17, 2020
- Prescriptions for Respiratory Meds, Antibiotics Down Over 30% in August: Survey
September 16, 2020
- Daiichi Sankyo Begins PII Study of ADC Patritumab for HER3-Positive Colorectal Cancer
September 16, 2020
- Novartis’ Mayzent now Available in Japan for Secondary Progressive MS
September 15, 2020
- J-TEC Files Mucosal Cell Sheet for Corneal Epithelial Stem Cell Deficiency in Japan
September 15, 2020
- Incyte Files Japan NDA for Pemigatinib for Cholangiocarcinoma
September 15, 2020
- Lilly Japan to Run Its First Voluntary Redundancy Program, 10% of Sales Force Targeted?
September 15, 2020
- AstraZeneca, PMDA Discussing Restart of COVID-19 Vaccine Trial in Japan
September 14, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…